

Integrum Q2 - Not that bad, but must exceed expectations

Redeye returns with a more in-depth take on the report following the conference call and chat with management. As stated in our initial take on the report, a neutral report is good at this point. However, for the company to regain investor confidence, it must overdeliver on market expectations on sales in the coming quarters. We revise our financial estimates downwards and increase our WACC, negatively impacting our fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Integrum Q2 - Not that bad, but must exceed expectations